A DNA methylation signature discriminates between excellent and non-response to lithium in patients with bipolar disorder type 1.

ABSTRACT: Lithium (Li) is the cornerstone maintenance treatment for bipolar disorders (BD), but response rates are highly variable. To date, no clinical or biological marker is available to reliably define eligibility criteria for a maintenance treatment with Li. We examined whether the prophylactic response to Li (assessed retrospectively) is associated with distinct blood DNA methylation profiles. Bisulfite-treated total blood DNA samples from individuals with BD type 1 (15 excellent-responders (LiERs) versus 11 non-responders (LiNRs)) were used for targeted enrichment of CpG rich genomic regions followed by high-resolution next-generation sequencing to identify differentially methylated regions (DMRs). After controlling for potential confounders we identified 111 DMRs that significantly differ be

SUBMITTER: Marie-Claire C 

PROVIDER: S-EPMC7376060 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature